Company intelligence / Profile preview
PDX Pharmaceuticals
Portland, Oregon, United Statespdxpharm.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Currently conducting IND enabling studies for drug candidates ARAC-02 and AIRISE-02, both funded by the National Cancer Institute (NCI). Planning to start clinical trials by 2025[1][4].
- Therapeutic areas
- Oncology
- Modalities
- Nanoparticle-based therapiessiRNAImmunotherapiesCombination therapies
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
National Cancer Institute (NCI)
Beyond the preview
Go deeper on PDX Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDX Pharmaceuticals.